NASDAQ:XENE
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.'s revenue was $7.5M in fiscal 2025. Free cash flow was −$279.9M, −3732.2% of revenue, and the diluted share count rose 1.7%.Summary generated from Xenon Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$7.5M
Revenue growthn/a
Revenue, 5-yr CAGR−25.3%
Gross marginn/a
Operating margin−4974.3%
Net margin−4612.1%
ROICn/a
Return on equity−51.8%
Debt / equityn/a
Free cash flow−$279.9M
FCF margin−3732.2%
Share count change+1.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 18 | 9 | 0 | 0 | 8 |
| Operating income | −79 | −129 | −214 | −279 | −373 |
| Net income | −79 | −125 | −182 | −234 | −346 |
| Free cash flow | −72 | −104 | −157 | −184 | −280 |
Recent filings
- 4Insider transaction report
Oct 1, 2026 - 4Insider transaction report
Oct 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KDirector or officer change
Jun 3, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026 - DEF 14AProxy statement
Apr 22, 2026